Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.
Yi-Ming ChenHsin-Hua ChenWen-Nan HuangYi-Hsing ChenTsu-Yi HsiehSheng-Shun YangJoung-Liang LanDer-Yuan ChenPublished in: International journal of rheumatic diseases (2019)
Baseline HBsAb positivity was a significant protective factor for rHBV in HBsAg-negative, HBcAb-positive RA patients receiving rituximab therapy.